Trial Profile
Apatinib Combined With Capecitabine Compared With Apatinib in the Treatment of Advanced Non-resectable Hepatocellular Carcinoma
Status:
Not yet recruiting
Phase of Trial:
Phase II
Latest Information Update: 22 May 2019
Price :
$35
*
At a glance
- Drugs Capecitabine (Primary) ; Rivoceranib (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
- 12 May 2017 Planned initiation date changed from 20 Apr 2017 to 20 May 2017.
- 20 Apr 2017 New trial record